MedTrace Logo

A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies

NCT04937166 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-11-10

No results posted yet for this study

Summary

This study will be divided into two parts, Parts A and B and will enroll patients with relapsed/refractory AML or MDS/chronic myelomonocytic leukemia (CMML) patients who have failed up to 2 prior therapeutic regimens.

Part A is a dose escalation study to explore the safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) profile of DSP107 when administered in combination with azacitidine (AZA).

Part B is a dose escalation study to explore the safety, efficacy, PK and PD profile of DSP107 when administered in combination with AZA and venetoclax (VEN).

Conditions

Interventions

BIOLOGICAL

DSP107

DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.

DRUG

Azacitidine

Azacitidine is an analog of the pyrimidine nucleoside cytidine.

DRUG

Venetoclax

Venetoclax is a B-cell lymphoma (BCL)-2 inhibitor

Sponsors & Collaborators

  • Kahr Medical

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-13
Primary Completion
2025-04-23
Completion
2025-10-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04937166 on ClinicalTrials.gov